Enhanced bimatoprost ophthalmic solution
DC CAFC
First Claim
Patent Images
1. A first composition administered once daily for lowering intraocular pressure in a person with glaucoma or ocular hypertension, the first composition comprising about 0.01% w/v bimatoprost and about 0.02% w/v benzalkonium chloride, wherein the first composition lowers intraocular pressure and results in less hyperemia as compared to the once daily administration of a second composition comprising 0.03% w/v bimatoprost and 0.005% w/v benzalkonium chloride.
1 Assignment
Litigations
0 Petitions
Accused Products
Abstract
A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein.
47 Citations
30 Claims
- 1. A first composition administered once daily for lowering intraocular pressure in a person with glaucoma or ocular hypertension, the first composition comprising about 0.01% w/v bimatoprost and about 0.02% w/v benzalkonium chloride, wherein the first composition lowers intraocular pressure and results in less hyperemia as compared to the once daily administration of a second composition comprising 0.03% w/v bimatoprost and 0.005% w/v benzalkonium chloride.
- 7. A first composition administered once daily for lowering intraocular pressure in a person with glaucoma or ocular hypertension, the first composition comprising about 0.01% w/v bimatoprost and about 0.02% w/v benzalkonium chloride, wherein the first composition lowers intraocular pressure without a substantial reduction in the intraocular pressure lowering benefit provided by the once daily administration of a second composition comprising 0.03% w/v bimatoprost and 0.005% w/v benzalkonium chloride.
- 15. A first composition for reducing the amount of bimatoprost administered to a person in a once daily treatment for glaucoma or ocular hypertension, the first composition comprising about 0.01% w/v bimatoprost and about 0.02% w/v benzalkonium chloride, wherein first the composition remains useful in treating glaucoma or ocular hypertension despite a lower concentration of bimatoprost as compared to the once daily administration of a second composition comprising 0.03% w/v bimatoprost and 0.005% w/v benzalkonium chloride.
- 23. A first composition for reducing the amount of bimatoprost administered to a person in a once daily treatment for glaucoma or ocular hypertension, wherein the first composition comprises about 0.01% w/v bimatoprost and about 0.02% w/v benzalkonium chloride, wherein the benzalkonium chloride concentration of the first composition increases the permeability of bimatoprost across corneal epithelial cell layers as compared to the once daily administration of a second composition comprising 0.03% w/v bimatoprost and 0.005% w/v benzalkonium chloride.
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
Litigation Data
-
Current AssigneeAllergan, Inc. (Canada) (Abbvie Incorporated)
-
Original AssigneeAllergan, Inc. (Canada) (Abbvie Incorporated)
-
InventorsChang, Chin-Ming, Chang, James N., Schiffman, Rhett M., Jordan, R. Scott, Chang-Lin, Joan-En
-
Primary Examiner(s)FAY, ZOHREH A
-
Application NumberUS13/370,574Publication NumberTime in Patent Office235 DaysField of Search514/530, 514/573US Class Current514/530CPC Class CodesA01N 33/12 Quaternary ammonium compoundsA61K 31/14 Quaternary ammonium compoun...A61K 31/165 having aromatic rings, e.g....A61K 31/557 Eicosanoids, e.g. leukotrie...A61K 31/5575 having a cyclopentane, e.g....A61K 47/02 Inorganic compoundsA61K 47/12 Carboxylic acids; Salts or ...A61K 9/0048 Eye, e.g. artificial tearsA61P 27/02 Ophthalmic agentsA61P 27/06 Antiglaucoma agents or mioticsA61P 27/14 Decongestants or antiallergics
